Selective Sigma-1 (sig1) Receptor Antagonists: Emerging Target for the Treatment of Neuropathic Pain

Publisher： Bentham Science Publishers

E-ISSN： 1875-6166|9|3|172-183

ISSN： 1871-5249

Source： Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Central Nervous System Agents), Vol.9, Iss.3, 2009-09, pp. : 172-183

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effect of tachykinin receptor antagonists in experimental neuropathic pain

By Coudore-Civiale M.-A.   Courteix C.   Eschalier A.   Fialip J.  

European Journal of Pharmacology, Vol. 361, Iss. 2, 1998-11 ,pp. : 175-184

Elsevier

Access to resources Recommend Favorite

Pharmacokinetic and pharmacodynamic considerations for NMDA receptor antagonists in the treatment of chronic neuropathic pain

By Niesters Marieke   Dahan Albert  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 8, Iss. 11, 2012-11 ,pp. : 1409-1417

Informa Healthcare

Access to resources Recommend Favorite

Cannabinoid CB 1 receptor upregulation in a rat model of chronic neuropathic pain

By Siegling A.   Hofmann H.A.   Denzer D.   Mauler F.   De Vry J.  

European Journal of Pharmacology, Vol. 415, Iss. 1, 2001-03 ,pp. : 5-7

Elsevier

Access to resources Recommend Favorite

VR1 Receptor Modulators as Potential Drugs for Neuropathic Pain

By  

Mini Reviews in Medicinal Chemistry, Vol. 3, Iss. 7, 2003-11 ,pp. : 729-748

Bentham Science Publishers

Access to resources Recommend Favorite

The ERK/MAPK pathway, as a target for the treatment of neuropathic pain

By Ma Weiya   Quirion Remi  

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 4, 2005-08 ,pp. : 699-713

Informa Healthcare

Access to resources Recommend Favorite